Epidemiological Insights, Genotypic Variations, and Treatment Efficacy in Chronic Hepatitis C Patients Treated with Direct-Acting Antivirals: Findings from a Cohort Study in Istanbul, Türkiye - Takeaways - MDSpire

Epidemiological Insights, Genotypic Variations, and Treatment Efficacy in Chronic Hepatitis C Patients Treated with Direct-Acting Antivirals: Findings from a Cohort Study in Istanbul, Türkiye

  • By

  • Semra Karaman Kamalı

  • Sevtap Senoglu

  • Sercan Kamalı

  • Yusuf Emre Ozdemir

  • Kadriye Kart Yasar

  • February 13, 2026

  • 0 min

Share

  • 1

    Chronic hepatitis C (CHC) is a significant global health issue, with approximately 50 million people affected worldwide.

  • 2

    In Türkiye, the prevalence of HCV infection is around 1%, influenced by various transmission routes and healthcare practices.

  • 3

    Direct-acting antivirals (DAAs) have improved access to treatment in Türkiye since 2016, enhancing outcomes for CHC patients.

  • 4

    The study assessed 233 CHC patients treated with DAAs, focusing on demographic, clinical characteristics, and treatment efficacy.

  • 5

    Findings indicate evolving HCV genotype patterns among younger individuals and high-risk groups, highlighting the need for tailored strategies.

Original Source(s)

Epidemiological Insights, Genotypic Variations, and Treatment Efficacy in Chronic Hepatitis C Patients Treated with Direct-Acting Antivirals: Findings from a Cohort Study in Istanbul, Türkiye

  • by Semra Karaman Kamalı, Sevtap Senoglu, Sercan Kamalı, Yusuf Emre Ozdemir, Kadriye Kart Yasar

  • February 13, 2026

Related Content

Indiana’s needle exchange programs are on the chopping block

Is Point-of-Care Hepatitis C Virus Testing Too Expensive?

RNA testing carries substantial cost burden for hospitals, study finds

  • January 14, 2026

  • 2 min
Calcium Intake and Bone Mineral Density in People With HIV and/or Chronic Hepatitis C